Xi Jiao

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Reply to: "NOTCH1: A Potential New Biomarker in the Era of Immunotherapy?" and "Caution in Interpreting NOTCH1 Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma".

Reply to: "NOTCH1: A Potential New Biomarker in the Era of Immunotherapy?" and "Caution in Interpreting NOTCH1 Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma".

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 11, 2025

EMB-01, a Tetravalent Bispecific Antibody, Inducing Co-Degradation of EGFR and c-Met for Enhanced Anti-Tumor Efficacy.

EMB-01, a Tetravalent Bispecific Antibody, Inducing Co-Degradation of EGFR and c-Met for Enhanced Anti-Tumor Efficacy.

Journal: Cancer science

Published: September 01, 2025

Development of a multi-epitope mRNA vaccine targeting tumor-associated antigens for esophageal squamous cell carcinoma.

Development of a multi-epitope mRNA vaccine targeting tumor-associated antigens for esophageal squamous cell carcinoma.

Journal: NPJ vaccines

Published: June 27, 2025

NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.

NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 03, 2025

An integrated prognosis prediction model based on real-word clinical characteristics for immunotherapy in advanced esophageal squamous cell carcinoma.

An integrated prognosis prediction model based on real-word clinical characteristics for immunotherapy in advanced esophageal squamous cell carcinoma.

Journal: Cancer immunology, immunotherapy : CII

Published: January 21, 2025

Impact of Psychological Factors on Survival in Metastatic Esophagogastric Cancer: Secondary Analysis of a Randomized Controlled Trial.

Impact of Psychological Factors on Survival in Metastatic Esophagogastric Cancer: Secondary Analysis of a Randomized Controlled Trial.

Journal: JCO oncology practice

Published: January 14, 2025

Prognostic and predictive value of angiogenesis-associated serum proteins for immunotherapy in esophageal cancer.

Prognostic and predictive value of angiogenesis-associated serum proteins for immunotherapy in esophageal cancer.

Journal: Journal for immunotherapy of cancer

Published: January 08, 2024

Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma.

Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma.

Journal: Signal transduction and targeted therapy

Published: November 22, 2023

From intestinal metaplasia to gastric cancer: Witnessing the rise of evil over time and space.

From intestinal metaplasia to gastric cancer: Witnessing the rise of evil over time and space.

Journal: Cancer cell

Published: October 06, 2023

The landscape of cancer research and cancer care in China.

The landscape of cancer research and cancer care in China.

Journal: Nature medicine

Published: August 21, 2023

Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.

Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.

Journal: Frontiers in immunology

Published: July 06, 2022

Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer.

Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer.

Journal: JAMA network open

Published: March 29, 2022

Showing 1-12 of 24

Last Updated: 09/26/2026